JAMA:肺动脉高压(PAH)的常见临床表现

2022-05-28 刘少飞 MedSci原创

肺动脉高压(PAH)是肺动脉高压(PH)的一种亚型,以肺动脉重构为特征。在美国,PAH 的患病率约为每 100 万成年人中有 10.6 例。未经治疗,PAH 会发展为右心衰竭和死亡。

肺动脉高压(PAH)是一种危及生命的疾病,其特征是由于肺血管阻力增加导致肺动脉压力升高。PAH 的症状是非特异性的,但通常包括劳力性呼吸困难和疲劳。在美国,PAH 的估计患病率为每 100 万成年人 10.6 人。未经治疗,PAH 通常会发展为右心室衰竭和死亡。治疗在过去十年中显着改善了结果。任何出现无法解释的劳力性呼吸困难的患者都应考虑该诊断。那PAH常见的临床表现有哪些呢?

临床表现:

PAH 的症状可能是非特异性的并且起病隐匿。在美国国立卫生研究院登记的 187 名 PAH 患者中,呼吸困难是 60% 的首发症状,尽管 98% 的人在诊断 PAH 时报告呼吸困难。也会出现疲劳 (19%)、近乎晕厥 (5%)、晕厥 (8%) 和胸痛 (7%)。对于晚期疾病,这些症状可能在极少的运动或休息时出现。

早期疾病的体格检查结果是微妙的。在 187 名患者中,93% 的患者第二心音响亮。其他明显的发现(右侧第三心音、三尖瓣反流杂音、颈静脉扩张增加、右心室隆起)发生在更晚期的疾病中。随着右心室功能障碍的恶化,可能会出现下肢水肿、腹胀和腹水。

诊断通常会延迟:REVEAL 登记中 21.1% 的患者(n = 2967)在诊断前症状已超过 2 年。年龄较小(<36 岁)以及同时存在哮喘和阻塞性睡眠呼吸暂停等常见呼吸系统疾病会增加诊断延迟。预后与就诊时的疾病严重程度相关。专家共识建议早期诊断和早期治疗可以提高生存率。需要高度怀疑患有无法解释的劳力性呼吸困难或疲劳的患者。

 

参考文献:

Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. DOI: 10.1001/jama.2022.4402. PMID: 35412560.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925607, encodeId=592d192560ec3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Apr 03 23:08:35 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224081, encodeId=e8861224081b5, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220602/67bfd4ca40954583991e58fdd4fcdc5e.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Thu Jun 02 16:17:54 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460206, encodeId=04d91460206c0, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Sat May 28 08:08:35 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243526, encodeId=1601124352697, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu May 26 20:08:35 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925607, encodeId=592d192560ec3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Apr 03 23:08:35 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224081, encodeId=e8861224081b5, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220602/67bfd4ca40954583991e58fdd4fcdc5e.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Thu Jun 02 16:17:54 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460206, encodeId=04d91460206c0, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Sat May 28 08:08:35 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243526, encodeId=1601124352697, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu May 26 20:08:35 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1925607, encodeId=592d192560ec3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Apr 03 23:08:35 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224081, encodeId=e8861224081b5, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220602/67bfd4ca40954583991e58fdd4fcdc5e.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Thu Jun 02 16:17:54 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460206, encodeId=04d91460206c0, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Sat May 28 08:08:35 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243526, encodeId=1601124352697, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu May 26 20:08:35 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-05-28 hb2010ye
  4. [GetPortalCommentsPageByObjectIdResponse(id=1925607, encodeId=592d192560ec3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Apr 03 23:08:35 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224081, encodeId=e8861224081b5, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220602/67bfd4ca40954583991e58fdd4fcdc5e.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Thu Jun 02 16:17:54 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460206, encodeId=04d91460206c0, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Sat May 28 08:08:35 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243526, encodeId=1601124352697, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu May 26 20:08:35 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-05-26 肿瘤克星

    JAMA上文章都是顶级的,谢谢梅斯及时上新

    0

相关资讯

JAMA:肺动脉高压(PAH)最新定义、病理生理学和患病率

PAH是肺动脉高压(PH)的一种亚型,以肺动脉重构为特征。在美国,PAH 的患病率约为每 100 万成年人 10.6 例。未经治疗,PAH 会发展为右心衰竭和死亡。

Heart:右心室重构在肺动脉高压中的重要性

最近的研究表明 PAH 进展的特征是 RV 尺寸和功能的变化(体积增加和射血分数降低),即使在明显稳定的患者中也是如此,这突出了RV在确定预后中的重要性。

肺动脉高压患者的远程6分钟步行试验:是否需要进一步验证?

肺动脉高压(PAH)是一种相对罕见的心肺血管疾病,六分钟步行测试(6MWT)可以了解慢性肺部疾病患者的功能状况、疾病严重程度和治疗效果。PAH患者的远程6分钟步行试验:是否需要进一步验证?

初始安立生坦联合5型磷酸二酯酶抑制剂对重度肺动脉高压患者右心室肺动脉耦合的超声心动图评估

肺动脉高压 (PAH) 是一种严重的临床综合征,其特征是肺血管阻力增加,导致右心衰竭和死亡。本研究的目的研究初始安立生坦联合 PDE5i 联合治疗对重度 PAH 患者 RVPAC 的影响和临床相关性。

西地那非并没有改善HFrEF和PH患者的症状、生活质量或运动能力

肺动脉高压(PAH)可能会并发射血分数降低的心力衰竭(HFrEF),并与大量症状负担和不良预后有关。西地那非可能对HFrEF和PHT的肺血流动力学、心功能和运动能力有好处。

肺动脉高压(PAH)的亚组都有哪些?

肺动脉高压 (PH) 的临床分类,其中 PAH 是一种亚型,对于了解 PAH 的诊断和治疗方法很重要。根据病理生理学、病因学和对治疗的反应,肺动脉高压进一步分为亚组。